Context Therapeutics (NASDAQ:CNTX) Announces Earnings Results

Context Therapeutics (NASDAQ:CNTX) announced its quarterly earnings results on Wednesday. The company reported ($0.15) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.10) by ($0.05), FiscalAI reports.

Context Therapeutics Stock Up 11.5%

CNTX traded up $0.07 during trading on Wednesday, hitting $0.69. The company’s stock had a trading volume of 2,320,160 shares, compared to its average volume of 2,293,434. Context Therapeutics has a twelve month low of $0.55 and a twelve month high of $3.62. The business’s fifty day simple moving average is $0.95 and its 200 day simple moving average is $1.93.

Wall Street Analysts Forecast Growth

Several research firms have recently weighed in on CNTX. Wall Street Zen lowered shares of Context Therapeutics from a “sell” rating to a “strong sell” rating in a report on Monday, July 20th. Maxim Group dropped their price target on shares of Context Therapeutics from $8.00 to $4.00 and set a “buy” rating on the stock in a research report on Tuesday, June 16th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Context Therapeutics in a report on Friday, July 17th. One equities research analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $6.17.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the business. Virtu Financial LLC purchased a new stake in Context Therapeutics in the 4th quarter worth $43,000. XTX Topco Ltd lifted its holdings in Context Therapeutics by 858.8% during the fourth quarter. XTX Topco Ltd now owns 101,605 shares of the company’s stock valued at $149,000 after purchasing an additional 91,008 shares in the last quarter. Quadrature Capital Ltd purchased a new position in Context Therapeutics during the fourth quarter valued at $68,000. Millennium Management LLC acquired a new stake in shares of Context Therapeutics in the fourth quarter valued at about $3,824,000. Finally, Marshall Wace LLP grew its position in shares of Context Therapeutics by 7,153.7% in the fourth quarter. Marshall Wace LLP now owns 2,593,198 shares of the company’s stock valued at $3,812,000 after purchasing an additional 2,557,448 shares during the period. Hedge funds and other institutional investors own 14.03% of the company’s stock.

About Context Therapeutics

Context Therapeutics (NASDAQ: CNTX) is a clinical-stage biopharmaceutical company focused on the discovery and development of precision therapies for genetically defined patient populations in oncology. The company’s research model centers on identifying novel targets and designing small-molecule and biologic candidates that address key drivers of tumor growth and resistance. Context Therapeutics leverages a biomarker-driven approach to maximize the probability of clinical response, tailoring its development programs to specific molecular subgroups within solid tumors.

With a pipeline advancing through early clinical trials, Context Therapeutics emphasizes strategic collaborations and academic partnerships to accelerate the translation of laboratory findings into patient-focused studies.